Although these treatments are currently not available for clinical use, determining the minimal PNP activity required for correcting the immune and neurological abnormalities associated with PNP deficiency would be an important step for the design and assessment of potential future clinical treatments. The gene discussed is PNP; the disease is purine nucleoside phosphorylase deficiency.